Regulating and monitoring the online GLP-1 market
Description
GLP-1 (glucagon-like peptide 1) medications are revolutionizing weight loss and diabetes care, but behind the hype lies a growing web of regulatory gaps, telehealth expansion and online pharmacy risks. This episode unpacks the opportunities -- and dangers -- shaping the future of these life-changing drugs.
Featuring: Scott Roth, Chief Executive Officer, LegitScript
Gerard Olsen, Director of Research, LegitScript
In today’s episode, we'll cover…
- The skyrocketing demand for GLP-1 medications and their influence on weight loss trends, including a 26% drop in bariatric surgeries
- How telehealth and online pharmacies are reshaping access to GLP-1 drugs -- and the risks posed by rogue sellers and counterfeit products
- The critical need for stronger regulatory enforcement and LegitScript's role in ensuring safety and transparency in the online healthcare market
To learn more about GLP-1 medications from all angles, check out our Pharma Life Sciences, Patient Engagement and Healthcare Payers sites.
To watch video clips from the conversation, subscribe to our YouTube channel, @HealthcareStrategies.
References:
Metabolic bariatric surgery in the GLP-1 era
Risks of online semaglutide without prescription
FDA updates on GLP-1 compounding policies
United States
